Hepatorenal Syndrome

Meet the patient

A 54-year-old man with known alcohol-related cirrhosis and tense ascites is admitted with drowsiness and a falling urine output. His creatinine has climbed from a baseline of 90 to 220 micromol/L over four days. He is afebrile, his blood pressure is 92/56 mmHg, and his urine is bland, with a urine sodium of just 6.^[1][10]

The night team wrote "pre-renal AKI, give fluids". The two questions that now decide his survival are the two that decide every cirrhotic with a rising creatinine: is this HRS, or something reversible hiding behind the cirrhosis? and if it is HRS, can I reverse it before he needs dialysis or a transplant? Everything below exists to answer those two questions at consultant depth.^[1][14]

The kidney that is innocent — what HRS is, and the three things it is not

HRS is a functional AKI: the kidney is structurally normal and is being starved by the circulation. Patients with HRS have normal kidney histology and no proteinuria, and kidney function can recover with pharmacological therapy or liver transplantation. That reversibility is the single fact that defines the syndrome and unifies its mechanism, its diagnosis and its treatment.^[1][3]

It is not a primary kidney disease. There is no glomerular, tubular or interstitial lesion — which is exactly why the diagnosis is one of exclusion, and why significant proteinuria or an abnormal ultrasound points away from HRS.^[1]

It is not volume-responsive pre-renal AKI. Hypovolaemia-induced AKI — from gastrointestinal losses, variceal haemorrhage or excessive diuresis — must be excluded first: intravenous albumin is the volume expander of choice in hospitalised patients with cirrhosis and ascites presenting with AKI, and renal function that recovers with volume expansion is not HRS.^[1][15]

It is not ATN — yet. HRS and acute tubular necrosis are increasingly considered a continuum rather than distinct entities, which is why the window to reverse HRS is treated as an emergency once the diagnosis is secure.^[3]

The modern fork — HRS-AKI vs HRS-NAKI

The old type 1 / type 2 labels still survive in vivas, but the modern framework speaks in tempo. The 1996 International Club of Ascites criteria defined HRS by a serum creatinine above 1.5 mg/dL and separated type 1 (rapidly progressive, creatinine rising above 2.5 mg/dL within two weeks) from type 2 (slowly progressive dysfunction). The 2015 revision harmonised the AKI definition with KDIGO, and type 1 became HRS-AKI, typically triggered by bacterial infections, while the chronic form became HRS-CKD (eGFR under 60 mL/min/1.73 m2 persisting beyond three months).^[1][2]

Enlarge

The modern AKI definition in cirrhosis is the foundation of every HRS diagnosis — reproduce it verbatim (creatinine-based, as current reviews state it). Conventional urine output and FeNa have significant limitations in advanced cirrhosis:^[1][3]

• An increase in serum creatinine of at least 0.3 mg/dL within 48 hours, OR
• An increase of at least 50 percent above baseline within 7 days.^[1][18]

^{[1] [2] [3] [7] [9]}

Etymology for viva gold: "hepato-renal" names the paradox the bedside clinician first noticed — the kidney fails while the liver sickens, yet the kidney itself is unmarked. The name survived because the observation was true: transplant the liver, and the kidney returns to work.^[3]

One in five, and the hits that bring it on

HRS accounts for 15 to 20 percent of AKI episodes in cirrhosis. In a prospective cohort of 234 non-azotaemic cirrhotics with ascites, the probability of developing HRS was 18 percent at one year and 39 percent at five years — so any cirrhotic with ascites is a patient in whom you are perpetually screening for HRS.^[1][10]

HRS rarely arrives alone — it is almost always a second hit on a fragile circulation. Remember it as SPINAL: Spontaneous bacterial peritonitis (bacterial infection is the typical trigger), Paracentesis without albumin, Infection, Nephrotoxic drugs, Alcoholic hepatitis and systemic inflammation, Low-output from a GI bleed.^[1][2]

The precipitant set, with the evidence behind each:^[1]

• Spontaneous bacterial peritonitis and other bacterial infection — bacterial infection is the typical trigger of HRS-AKI; norfloxacin primary prophylaxis in high-risk ascites delays the development of HRS and improves survival.^[1][12]
• Large-volume paracentesis without albumin — in the landmark randomised trial, 11 of 53 patients tapped without albumin developed renal impairment or severe hyponatraemia versus 1 of 52 tapped with albumin.^[11]
• Gastrointestinal bleeding and over-diuresis — both cause the hypovolaemia-induced AKI that must be excluded before HRS is labelled.^[1]
• Nephrotoxic drugs — these cause ATN rather than HRS; in advanced cirrhosis the kidney also loses its prostaglandin-mediated vasodilator protection, which is insufficient to maintain renal perfusion.^[1]
• Systemic inflammation — bacterial translocation with pathogen- and damage-associated molecular patterns, and the systemic inflammation of alcoholic hepatitis, exacerbate the circulatory dysfunction.^[1][2]

Risk modifiers that predict HRS occurrence in a cirrhotic with ascites: in the prospective cohort, only three variables were independent predictors — low serum sodium concentration, high plasma renin activity, and absence of hepatomegaly. Arterial pressure, urinary sodium excretion, serum and urine osmolality, free water clearance and plasma norepinephrine all carried univariate predictive weight, and a cirrhotic cardiomyopathy phenotype with reduced cardiac output contributes to the circulatory failure.^[10][1]

Why the kidney shuts down — the vasodilation cascade

The kidney is an innocent bystander in a systemic haemodynamic collapse. The dominant mechanism is progressive splanchnic arterial vasodilation mediated by nitric oxide, carbon monoxide and endocannabinoids, amplified by a cardiac and inflammatory second hit.^[1][2]

Enlarge

Step 1 — Splanchnic vasodilation (the first hit). Portal hypertension from increased intrahepatic vascular resistance triggers progressive splanchnic arterial vasodilation mediated by nitric oxide, carbon monoxide and endocannabinoids. The splanchnic bed dilates, sequesters blood, and drops the systemic vascular resistance; early cirrhosis compensates with a hyperdynamic circulation.^[1]

Step 2 — The effective arterial blood volume collapses. Despite high total blood volume, effective arterial blood volume is critically low. The body reads this as underfilling.^[1]

Step 3 — The three vasoconstrictor systems fire. Compensatory neurohumoral activation switches on the classic antinatriuretic trio:^[1]

• RAAS — angiotensin II constricts the renal arteriole; aldosterone retains sodium.
• Sympathetic nervous system — catecholamines constrict the renal bed and release renin.
• Arginine vasopressin (non-osmotic) — drives water retention and dilutional hyponatraemia; low serum sodium is one of the three independent predictors of HRS occurrence.^[1][10]

Step 4 — Renal vasoconstriction wins. Impaired renal autoregulation and insufficient prostaglandin-mediated vasodilation fail to hold the renal perfusion, and profound renal arterial vasoconstriction severely impairs renal blood flow and GFR. This prostaglandin dependence is exactly why prostaglandin-inhibiting drugs are hazardous here.^[1]

Step 5 — The second hit. Splanchnic vasodilation alone is not sufficient. A fall in cardiac output (the cirrhotic cardiomyopathy phenotype) and systemic inflammation — driven by bacterial translocation and release of pathogen- and damage-associated molecular patterns — further exacerbate the circulatory dysfunction and contribute to multiorgan failure.^[1][2]

Why the urine is bland. The kidney is structurally normal with no proteinuria, and sodium and water retention under the vasoconstrictor systems is extreme — urinary sodium excretion is one of the variables that predicts HRS occurrence in cirrhosis with ascites.^[1][10] Do not use FeNa to prove HRS or ATN: in a prospective cirrhosis-AKI cohort, median FeNa was 0.10 percent in HRS, 0.27 percent in volume-responsive pre-renal AKI, and 0.31 percent in ATN (no difference between pre-renal and ATN, P = 0.54). The discriminator is the albumin challenge plus the rest of the exclusion list, not a FeNa cut-off of 2 percent.^[19][3]

The bedside round — find the precipitant, not the diagnosis

Examination in suspected HRS rarely makes the diagnosis; its job is to find the precipitant and grade the decompensation. Run it in this order:^[1]

• Vital signs — arterial pressure (a univariate predictor of HRS occurrence) and a careful volume-status assessment: JVP, peripheral oedema, daily weight, strict fluid balance, and a urinary catheter for accurate hourly output.^[10]
• Stigmata of chronic liver disease and decompensation — jaundice, spider naevi, palmar erythema, parotid enlargement, gynaecomastia, testicular atrophy, ascites, caput medusae, asterixis (encephalopathy), hepatic hydrothorax.
• Hunt the precipitant — this is mandatory and high-yield:
  • Diagnostic ascitic tap in every cirrhotic with ascites and AKI — bacterial infection is the typical HRS trigger, and SBP must be excluded before the label is written.^[1]
  • GI bleed — melaena or haematemesis, signs of shock; variceal haemorrhage is a recognised cause of hypovolaemic AKI.^[1]
  • Drug history — nephrotoxic medications cause ATN and must be stopped.^[1]
  • Recent paracentesis without albumin — the classic iatrogenic precipitant.^[11]

Investigations — confirm the AKI, exclude everything else

The tests serve two purposes: confirm the AKI, and exclude every alternative before you label it HRS.^[1]

First-line tests:^[1]

• Serum creatinine — stage the AKI by the modern definition (rise of at least 0.3 mg/dL within 48 hours, or at least 50 percent above baseline within 7 days) and compare with the patient's own baseline.^[1]
• Urea and electrolytes — hyponatraemia is one of the three independent predictors of HRS occurrence.^[10]
• LFTs and coagulation — to define the liver failure.
• Urinalysis and microscopy — HRS has no significant proteinuria; the kidney is structurally normal.^[1]
• Urine sodium — urinary sodium excretion carries predictive weight for HRS occurrence, though no single urine index makes the diagnosis.^[10]
• Renal tract ultrasound — postrenal obstruction is rare but must be excluded.^[1]
• Diagnostic ascitic tap — exclude SBP: in cirrhosis with SBP, renal function frequently becomes impaired and this carries a high mortality, which albumin therapy reduces.^[4]
• Blood cultures, lactate, FBC, CRP — detect sepsis.

Excluding structural kidney disease is a formal requirement of the diagnosis. HRS is defined by markedly reduced GFR without substantial histological changes in the kidney and no proteinuria — significant proteinuria or haematuria points to glomerular disease instead and mandates a search for it.^[1]

Emerging tools — novel GFR equations developed specifically for patients with liver disease estimate kidney function better than creatinine, and biomarkers have been useful in differentiating ATN from HRS at an early stage.^[14][3]

The diagnostic criteria — state them in this order

This is the single most exam-reproduced item in HRS. State all five:^[1][18]

1. Cirrhosis with ascites — HRS occurs in patients with cirrhosis and ascites.^[7]
2. AKI by the modern ICA-aligned definition — creatinine rise of at least 0.3 mg/dL within 48 hours, or at least 50 percent above baseline within 7 days. Urine output and FeNa have significant limitations here and do not make the diagnosis.^[1][3]
3. No recovery after diuretic withdrawal and albumin — albumin 1 g/kg of body weight (maximum 100 g) for two consecutive days; intravenous albumin is the volume expander of choice, and renal function that recovers with volume expansion is not HRS.^[18][15]
4. Other causes of AKI excluded — hypovolaemia (gastrointestinal losses, variceal haemorrhage, excessive diuresis), shock or prolonged ischaemia, nephrotoxic medications, and postrenal obstruction.^[1]
5. No structural kidney injury — no significant proteinuria, normal kidney histology.^[1]

The differential — exclusion is the discriminator

The central exam task is distinguishing HRS from every other cause of AKI in cirrhosis. Reproduce this table.^[1][3]

The single most-tested distinction: HRS vs ATN. Differentiating them is challenging yet important, because vasoconstrictors are not justified for the treatment of ATN — and the two are increasingly considered a continuum rather than distinct entities. Emerging biomarkers may help differentiate them and provide prognostic information.^[3][14]

Resuscitation — the first-contact bundle

Enlarge

The immediate bundle for a cirrhotic with new AKI:^[1][15]

• ABCDE, oxygen if hypoxic, IV access, bloods, diagnostic ascitic tap, urinalysis and microscopy, ECG, renal ultrasound.
• Volume expansion with intravenous albumin — the volume expander of choice in hospitalised patients with cirrhosis and ascites presenting with AKI. If renal function recovers with volume expansion, this was not HRS.^[15]
• Stop all nephrotoxic drugs — nephrotoxic medications cause ATN and must be withdrawn.^[1]
• Identify and treat any precipitant aggressively:
  • SBP — treat with an antibiotic plus albumin 1.5 g/kg of body weight at the time of diagnosis, followed by 1 g/kg on day 3 — the landmark trial regimen, which reduced renal impairment from 33 percent to 10 percent and in-hospital mortality from 29 percent to 10 percent.^[4]
  • Variceal bleed — vasoactive drugs should be started as soon as the diagnosis is suspected, before endoscopy, and continued for 2 to 5 days after haemostasis; octreotide is the vasoactive drug of choice on safety grounds.^[15]
  • Other sepsis — source control and broad-spectrum antibiotics per local protocol.
• Treat life-threatening complications concomitantly — the hyperkalaemia, acidosis and encephalopathy of decompensation, alongside the liver failure itself.^[1]

Definitive therapy — vasoconstrictor plus albumin, then transplant

Once HRS is confirmed, the ladder is vasoconstrictor plus albumin, escalating to renal replacement therapy, with liver transplantation the only curative treatment.^[3][15]

Step 1 — Confirm the diagnosis and exclude the alternatives. Complete the volume expansion, urine microscopy, ascitic tap, ultrasound and nephrotoxin review before declaring HRS.^[1]

Step 2 — Terlipressin plus albumin (the first-line regimen). Pooled series reported renal-function improvement in 35 to 45 percent of patients with AKI-HRS.^[7] In CONFIRM, verified reversal occurred in 32 percent versus 17 percent with placebo, but 90-day death was 51 percent versus 45 percent and death from respiratory disorders was 11 percent versus 2 percent — so do not cite CONFIRM as a mortality win.^[5] Terlipressin is the vasoactive drug of choice, with concurrent albumin considered in light of the patient's volume status; it does not require ICU monitoring and can be given through a peripheral line.^[15]

^{[3] [6] [5] [15]}

Definitions of response (from the pivotal CONFIRM trial):^[5]

• Verified reversal of HRS — two consecutive serum creatinine measurements of 1.5 mg/dL or less, at least 2 hours apart, plus survival without renal-replacement therapy for at least 10 days after completing treatment.^[5]
• HRS reversal (secondary definition) — any serum creatinine of 1.5 mg/dL or less during the first 14 days: 39 percent with terlipressin versus 18 percent with placebo.^[5]
• Non-responders exist — not all patients respond to terlipressin, and even responders carry high early mortality without transplantation.^[3]

Step 3 — Noradrenaline (norepinephrine), the ICU alternative. In the Indian randomised pilot trial, noradrenaline 0.5 to 3.0 mg/hour with albumin matched terlipressin 0.5 to 2 mg six-hourly with albumin — 50 percent of patients in each group reached HRS reversal — and noradrenaline was significantly less expensive.^[8] AGA lists norepinephrine among the vasoactive drugs for HRS-AKI; unlike terlipressin it is an infusion that in practice needs a central line and usually ICU.^[15][3]

Step 4 — Midodrine plus octreotide (the inferior fallback). Where terlipressin is unavailable, midodrine 7.5 mg thrice daily increased to a maximum of 12.5 mg thrice daily, plus octreotide 100 micrograms subcutaneously thrice daily up to 200 micrograms thrice daily, plus albumin is used — but in the head-to-head randomised trial recovery of renal function was 28.6 percent versus 70.4 percent in favour of terlipressin, and the Cochrane network meta-analysis found lower recovery from HRS with albumin plus midodrine plus octreotide than with albumin plus terlipressin.^[6][16]

Step 5 — Renal replacement therapy (RRT). Initiate for the standard AKI indications when vasoconstrictors fail or are contraindicated. Pretransplant treatment with terlipressin plus albumin decreased the need for renal replacement therapy both before and after transplantation at 12 months — pharmacological bridging has real transplant value.^[17]

Step 6 — Liver transplantation (the only curative treatment). Liver transplantation is the only curative treatment of HRS; even responders carry high early mortality without it, and emerging biomarkers may guide the decision for simultaneous liver-kidney transplantation.^[3]

TIPS (transjugular intrahepatic portosystemic shunt) reduces the portal pressure gradient and improves renal function in selected patients — in the prospective study of type I HRS, renal function improved in 6 of 7 patients (creatinine falling from about 5 to about 1.8 mg/dL, GFR rising from about 9 to about 27 mL/min), with suppression of the renin-angiotensin and sympathetic systems; mean survival after TIPS was about 4.7 months.^[9]

Prevention — the bundle that stops HRS happening

The high-yield preventive bundle — most HRS is preventable, and prevention is cheaper and more available than cure:^[12][15]

• Primary SBP prophylaxis with norfloxacin — in cirrhotics with low-protein ascitic fluid (under 15 g/L) plus either advanced liver failure (Child-Pugh 9 or more with bilirubin 3 mg/dL or more) or impaired renal function (creatinine 1.2 mg/dL or more, blood urea nitrogen 25 mg/dL or more, or serum sodium 130 mEq/L or less): primary prophylaxis reduced the one-year probability of SBP from 61 percent to 7 percent, delayed the development of hepatorenal syndrome, and improved survival.^[12]
• Albumin during large-volume paracentesis — intravenous albumin 8 g per litre of ascites removed should be given when more than 5 L is tapped.^[18][15] In the landmark randomised trial, 40 g after each tap (4 to 6 L/day) prevented the renal impairment and severe hyponatraemia that developed in 11 of 53 patients tapped without albumin versus 1 of 52 tapped with albumin.^[11]
• Albumin after SBP — the landmark regimen (1.5 g/kg at diagnosis, 1 g/kg on day 3, with cefotaxime) reduces the incidence of renal impairment and death compared with antibiotic alone.^[4]
• Avoid nephrotoxins — nephrotoxic medications cause ATN and must be avoided in decompensated cirrhosis.^[1]
• Albumin is not a tonic — it should not be used in cirrhosis with uncomplicated ascites, and vasoconstrictors should not be used for uncomplicated ascites, after large-volume paracentesis, or in SBP.^[15]

Subtypes and scenarios

• HRS-AKI (former type 1) — rapidly progressive renal failure, typically triggered by bacterial infections; the malignant form, managed as above; associated with extremely short survival untreated.^[1][10]
• HRS-NAKI (former type 2 / chronic) — moderate, stable or slowly progressive renal dysfunction without an obvious precipitant, dominated by refractory ascites; HRS-CKD means eGFR under 60 mL/min/1.73 m2 persisting beyond three months. TIPS improves renal function in selected patients; transplant assessment follows.^[2][1][9]
• HRS in acute-on-chronic liver failure — systemic inflammation, oxidative stress and bile salt-related tubular damage contribute alongside the haemodynamic derangement, explaining why some patients do not respond to vasoconstrictors plus albumin.^[2]
• Post-SBP renal impairment — albumin 1.5 g/kg at diagnosis and 1 g/kg on day 3 with cefotaxime reduces the incidence of renal impairment and death after SBP — a board-rewarded preventive intervention.^[4]
• HRS-CKD / coexisting CKD — distinguishing prolonged HRS from intrinsic CKD is difficult; biomarkers may inform the decision for simultaneous liver-kidney transplantation.^[3]

Complications and the traps that cost lives

Complications of HRS itself:^[3]

• Progression to irreversible ATN — HRS and ATN are considered a continuum rather than distinct entities; the untreated functional AKI converts to structural injury.^[3]
• Death — even among terlipressin responders, early mortality rates are very high in the absence of liver transplantation.^[3]
• Hyponatraemia and sodium retention — low serum sodium is one of the three independent predictors of HRS occurrence.^[10]

Complications of terlipressin therapy: serious adverse events including respiratory failure (the CONFIRM trial safety signal) — AGA guidance contraindicates terlipressin in hypoxaemia and in ongoing coronary, peripheral or mesenteric ischaemia, and advises caution in ACLF grade 3.^[5][15]

Classic pitfalls — each is examinable:^[1][3]

• Volume overload — concurrent albumin must be weighed against the patient's volume status; the respiratory failure signal demands caution in volume-overloaded patients.^[15][5]
• Misdiagnosis — treating ATN or glomerular disease as HRS (or vice versa): differentiating HRS from ATN is challenging yet important because vasoconstrictors are not justified for ATN.^[3]
• Missing the hypovolaemic cause — gastrointestinal losses, variceal haemorrhage or excessive diuresis cause an AKI that recovers with volume expansion; failing to exclude them mislabels the patient.^[1]
• The SBP miss — failing to tap a cirrhotic with ascites and AKI misses the typical bacterial trigger of HRS-AKI.^[1]
• False reassurance of a 'normal' creatinine — creatinine overestimates GFR by about half in cirrhotics with reduced GFR.^[13]

Prognosis and disposition

HRS carries an appalling prognosis untreated. In the prospective cohort, HRS in cirrhosis with ascites was associated with extremely short survival. Even among terlipressin responders, early mortality remains very high without liver transplantation.^[10][3]

Terlipressin plus albumin reversed renal function in 35 to 45 percent of AKI-HRS in pooled series; CONFIRM verified reversal in 32 percent versus 17 percent with placebo, without a 90-day mortality benefit (51 percent versus 45 percent died).^[7][5]

Predictors of poor outcome: low serum sodium and high plasma renin activity independently predict HRS occurrence in cirrhosis with ascites, and AGA guidance cautions that terlipressin's benefits may not outweigh its risks when creatinine exceeds 5 mg/dL or MELD is 35 or higher.^[10][15]

Disposition: HRS is an in-hospital diagnosis; terlipressin does not require ICU monitoring and can run through a peripheral line. All patients should be assessed for liver transplantation — pretransplant terlipressin reduced both pre- and post-transplant RRT need at 12 months.^[15][17]

Special populations

• Paediatric HRS — rare; the same functional principles apply and liver transplantation is definitive.^[3]
• Pregnancy — rare; management principles are the same, with obstetric and hepatology multidisciplinary input.
• Elderly cirrhotic — atypical presentation, comorbid kidney and cardiovascular disease, higher nephrotoxicity from polypharmacy, worse tolerance of volume shifts — emphasise precipitant prevention.^[1]
• Immunocompromised (post-transplant, HIV, on immunosuppression) — higher risk of infection precipitating HRS.^[1]
• Resource-limited settings — norfloxacin primary prophylaxis in high-risk ascites, albumin at large-volume paracentesis and after SBP are the affordable, outcome-changing interventions; noradrenaline is significantly less expensive than terlipressin when a vasoconstrictor is needed.^{[12][11][4][8]}

Evidence, guidelines and regional differences

Landmark trials and what they changed:^[1]

• CONFIRM (Wong et al., NEJM 2021)^[5] — pivotal randomised trial of terlipressin plus albumin versus placebo for HRS-1, for up to 14 days: verified reversal in 32 percent versus 17 percent, with serious adverse events including respiratory failure.
• Angeli et al., J Hepatol 2019^[2] — position paper completing the reclassification of HRS-1 into HRS-AKI and recognising systemic inflammation, oxidative stress and bile salt-related tubular damage as contributors.
• Sort et al., NEJM 1999^[4] — landmark trial of albumin (1.5 g/kg at diagnosis, 1 g/kg on day 3) with cefotaxime after SBP: renal impairment 10 percent versus 33 percent, in-hospital mortality 10 percent versus 29 percent.
• Cavallin et al., Hepatology 2015^[6] — head-to-head randomised trial: terlipressin plus albumin recovered renal function in 70.4 percent versus 28.6 percent with midodrine and octreotide plus albumin.
• Best et al., Cochrane 2019^[16] — network meta-analysis of 25 trials: all evidence low or very low certainty; no evidence of a difference between regimens on mortality; albumin plus midodrine plus octreotide and albumin alone had lower recovery from HRS than albumin plus terlipressin.
• Weinberg et al., Liver Transpl 2024^[17] — post hoc analysis of CONFIRM transplant recipients: pretransplant terlipressin plus albumin decreased the need for RRT both pre- and post-transplant.
• Ginès et al., Gastroenterology 1993^[10] — prospective cohort of 234 cirrhotics with ascites: HRS probability 18 percent at 1 year, 39 percent at 5 years; independent predictors low serum sodium, high plasma renin activity, absence of hepatomegaly.

Controversies: bolus versus continuous-infusion terlipressin (the best route is not yet defined); terlipressin versus noradrenaline (no evidence of a difference, cost and availability differ); the respiratory failure signal; albumin supply and cost in resource-limited settings; TIPS in HRS; simultaneous liver-kidney transplantation allocation.^[7][16][9]

The mantra

Exclude before you declare; albumin before terlipressin; terlipressin before transplant. The kidney is innocent until the circulation proves otherwise.^[1][3]

Ward-round test

A cirrhotic with ascites and a creatinine rising from 90 to 220 over four days — first three moves?ShowHide

Tap the ascites (bacterial infection is the typical trigger — exclude SBP), expand volume with intravenous albumin and treat hypovolaemia (albumin is the volume expander of choice; recovery with volume expansion means this was not HRS), and stop every nephrotoxin (nephrotoxic drugs cause ATN, not HRS). Only when other causes are excluded — hypovolaemia, shock or ischaemia, nephrotoxins, structural kidney disease — is it HRS.^[1][15]

Bland urine with a very low urine sodium — is this HRS?ShowHide

Not on urine chemistry alone. Urinary sodium excretion is one of the variables that predicts HRS occurrence in cirrhosis with ascites — it flags risk, it does not make the diagnosis. Median FeNa was 0.10 percent in HRS, 0.27 percent in volume-responsive pre-renal AKI, and 0.31 percent in ATN — so a FeNa under 1 percent does not distinguish these phenotypes, and a FeNa of 2 percent is not a reliable ATN marker in cirrhosis. Separating HRS from ATN is challenging yet important, because vasoconstrictors are not justified for ATN; the two are increasingly seen as a continuum, and emerging biomarkers may help differentiate them and inform prognosis.^{[10][19][3][14]}

HRS confirmed — what is the regimen, and what is the target?ShowHide

Terlipressin by IV bolus 0.5 to 1 mg every 4 to 6 hours (maximum 2 mg every 4 hours) or by continuous infusion 2 to 12 mg/day, PLUS albumin 1 g/kg on day 1 then 20 to 40 g/day, for up to 14 days, targeting verified reversal: two consecutive creatinine values of 1.5 mg/dL or less at least 2 hours apart, with survival free of renal replacement therapy for at least 10 days. Noradrenaline 0.5 to 3.0 mg/hour with albumin is a cheaper ICU alternative (50 percent reversal in a 40-patient pilot). The only curative treatment is liver transplantation.^[3][6][5][8]

A cirrhotic is given terlipressin and develops breathlessness and falling saturations — what happened?ShowHide

The CONFIRM trial respiratory failure signal. Terlipressin was associated with serious adverse events including respiratory failure in the pivotal trial, and AGA guidance contraindicates it outright in hypoxaemia. Assess volume status — concurrent albumin must be weighed against it — and stop the drug.^[5][15]

Name the single most rewarding preventive intervention in cirrhosisShowHide

Albumin 1.5 g/kg of body weight at diagnosis and 1 g/kg on day 3, with the antibiotic, after SBP — the landmark regimen: renal impairment fell from 33 percent to 10 percent and in-hospital mortality from 29 percent to 10 percent.^[4]

References19ShowHide

1. [1]Girish V, Ranasinghe IR, Rout P Hepatorenal Syndrome StatPearls [Internet], 2026.PMID 28613606
2. [2]Angeli P, Garcia-Tsao G, Nadim MK, et al. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document J Hepatol, 2019.PMID 31302175
3. [3]Francoz C, Durand F, Kahn JA, Nadim MK Hepatorenal Syndrome Clin J Am Soc Nephrol, 2019.PMID 30996046
4. [4]Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis N Engl J Med, 1999.PMID 10432325
5. [5]Wong F, Pappas SC, Curry MP, et al. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome N Engl J Med, 2021.PMID 33657294
6. [6]Cavallin M, Kamath PS, Merli M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial Hepatology, 2015.PMID 25644760
7. [7]Cavallin M, Fasolato S, Marenco S, Piano S, Tonon M, Angeli P The Treatment of Hepatorenal Syndrome Dig Dis, 2015.PMID 26159272
8. [8]Sharma P, Kumar A, Sharma BC, Sarin SK An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response Am J Gastroenterol, 2008.PMID 18557715
9. [9]Guevara M, Ginès P, Bandi JC, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems Hepatology, 1998.PMID 9696006
10. [10]Ginès A, Escorsell A, Ginès P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites Gastroenterology, 1993.PMID 8514039
11. [11]Ginès P, Titó L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis Gastroenterology, 1988.PMID 3360270
12. [12]Fernández J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis Gastroenterology, 2007.PMID 17854593
13. [13]Caregaro L, Menon F, Angeli P, et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis Arch Intern Med, 1994.PMID 8285815
14. [14]Khemichian S, Francoz C, Nadim MK Advances in management of hepatorenal syndrome Curr Opin Nephrol Hypertens, 2021.PMID 34397647
15. [15]Garcia-Tsao G, Abraldes JG, Rich NE, et al. AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review Gastroenterology, 2024.PMID 37978969
16. [16]Best LM, Freeman SC, Sutton AJ, et al. Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis Cochrane Database Syst Rev, 2019.PMID 31513287
17. [17]Weinberg EM, Wong F, Vargas HE, et al. Decreased need for RRT in liver transplant recipients after pretransplant treatment of hepatorenal syndrome-type 1 with terlipressin Liver Transpl, 2024.PMID 37801553
18. [18]European Association for the Study of the Liver EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis J Hepatol, 2018.PMID 29653741
19. [19]Belcher JM, Sanyal AJ, Peixoto AJ, et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury Hepatology, 2014.PMID 24375576